Implication of 5-HT2 receptor subtypes in the mechanism of action of antidepressants in the four plates test

Psychopharmacology

Volumn 179, Issue 2, 2005, Pages 418-429

  Dhonnchadha, Bríd Áine Nic ^a   Ripoll, Nadège ^a   Clénet, Florence ^a   Hascoët, Martine ^a   Bourin, Michel ^a  

^a UNIVERSITÉ DE NANTES   (France)

Author keywords

5 HT2 receptor ligands; Four plates test; Mice; Paroxetine; Venlafaxine

Indexed keywords

1 [5 (2 THIENYLMETHOXY) 3 INDOLYL] 2 PROPANAMINE; 1,2,3,5 TETRAHYDRO 5 METHYL 1 (3 PYRIDYLCARBAMOYL)PYRROLO[2,3 F]INDOLE; 2 (6 CHLORO 5 FLUORO 1 INDOLYL) 1 METHYLETHYLAMINE; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; ANTIDEPRESSANT AGENT; EPLIVANSERIN; PAROXETINE; RS 10 2221; SEROTONIN 2 RECEPTOR; SEROTONIN 2A ANTAGONIST; SEROTONIN 2C ANTAGONIST; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG; VENLAFAXINE; 4 AMINOBUTYRIC ACID A RECEPTOR; CYCLOHEXANOL DERIVATIVE; HYPNOTIC SEDATIVE AGENT; SEROTONIN 2A RECEPTOR; SEROTONIN 2B RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN ANTAGONIST;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PUNISHMENT; ANIMAL; AVOIDANCE BEHAVIOR; ELECTRIC SHOCK; MOTOR ACTIVITY; STIMULATION;

ANIMALS; ANTIDEPRESSIVE AGENTS; AVOIDANCE LEARNING; CYCLOHEXANOLS; ELECTROSHOCK; HYPNOTICS AND SEDATIVES; MALE; MICE; MOTOR ACTIVITY; PAROXETINE; PUNISHMENT; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTOR, SEROTONIN, 5-HT2B; RECEPTOR, SEROTONIN, 5-HT2C; RECEPTORS, GABA-A; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; SEROTONIN UPTAKE INHIBITORS; STIMULATION, CHEMICAL;

EID: 17644376830     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-004-2044-y     Document Type: Article

References (62)

1. Ables AZ, Baughman OL III (2003) Antidepressants: update on new agents and indications. Am Fam Phys 67:547-554
2. Ardid D, Marty H, Fialip J, Privat AM, Eschalier A, Lavarenne J (1992) Comparative effects of different uptake inhibitor antidepressants in two pain tests in mice. Fundam Clin Pharmacol 6:75-82
3. Beijamini V, Andreatini R (2003) Effects of Hypericum perforatum and paroxetine on rat performance in the elevated T-maze. Pharmacol Res 48:199-207
4. Besson A, Haddjeri N, Blier P, De Montigny C (2000) Effects of the co-administration of mirtazapine and paroxetine on serotonergic neurotransmission in the rat brain. Eur Neuropsychopharmacol 10:177-188
5. Beyer CE, Boikess S, Luo B, Dawson LA (2002) Comparison of the effects of antidepressants on norepinephrine and serotonin concentrations in the rat frontal cortex: an in-vivo microdialysis study. J Psychopharmacol 16:297-304
6. Boissier JR, Simon P (1965) Action of caffeine on the spontaneous motility of the mouse. Arch Int Pharmacodyn Ther 158:212-221
7. Boissier JR, Simon P, Aron C (1968) A new method for rapid screening of minor tranquillizers in mice. Eur J Pharmacol 4:145-151
8. Borsini F, Podhorna J, Marazziti D (2002) Do animal models of anxiety predict anxiety-like effects of antidepressants. Psychopharmacology 163:121-141
9. Bourin M, Lambert O (2002) Pharmacotherapy of anxious disorders. Hum Psychopharmacol 17:383-400
10. Bourin M, Chue P, Guillon Y (2001) Paroxetine: a review. CNS Drug Rev 7:25-47
11. Bourin M, David DJ, Jolliet P, Gardier A (2002) Mechanism of action of antidepressants and therapeutic perspectives. Therapie 57:385-396
12. Briley M (2003) New hope in the treatment of painful symptoms in depression. Curr Opin Invest Drugs 4:42-45
13. Cusack B, Nelson A, Richelson E (1994) Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology 114:559-565
14. Damjanoska KJ, Muma NA, Zhang Y, D'Souza DN, Garcia F, Carrasco GA, Kindel GH, Haskins KA, Shankaran M, Petersen BR, Van de Kar LD (2003) Neuroendocrine evidence that (S)-2-(chloro-5-fluoro-indol-1-yl)-1- methylethylamine fumarate (Ro 60-0175) is not a selective 5- hydroxytryptamine(2C) receptor agonist. J Pharmacol Exp Ther 304:1209-1216
15. David DJ, Bourin M, Jego G, Przybylski C, Jolliet P, Gardier AM (2003) Effects of acute treatment with paroxetine, citalopram and venlafaxine in vivo on noradrenaline and serotonin outflow: a microdialysis study in Swiss mice. Br J Pharmacol 140: 1128-1136
16. Davidson JR, Dupont RL, Hedges D, Haskins JT (1999) Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J Clin Psychiatry 60:528-535
17. Deakin JF, Graeff FG, Guimaraes FS (1993) Clinical implication of microdialysis findings. Trends Pharmacol Sci 14:263
18. Di Matteo V, Cacchio VM, Di Giulio C, Esposito E (2002) Role of serotonin 2C receptors in the control of brain dopaminergic function. Pharmacol Biochem Behav 71:727-734
19. Duman EN, Kesim M, Kadioglu M, Yaris E, Kalyoncu NI, Erciyes N (2004) Possible involvement of opioide and serotonergic mechanisms in antinociceptive effect of paroxetine in acute pain. J Pharmacol Sci 94:161-165
20. 1A receptor antagonist WAY100635. Br J Pharmacol 130:1713-1719
21. Fasmer OB, Hunskaar S, Hole K (1989) Antinociceptive effects of serotonergic reuptake inhibitors in mice. Neuropharmacology 28:1363-1366
22. Felton TM, Kang TB, Hjorth S, Auerbach SB (2003) Effects of selective serotonin and serotonin/noradrenaline reuptake inhibitors on extracellular serotonin in rat diencephalon and frontal cortex. Naunyn Schmiedebergs Arch Pharmacol 367:297-305
23. Ferreri M, Lavergne F, Berlin I, Payan C, Puech AJ (2001) Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone. Acta Psychiatr Scand 103:66-72
24. Fuller RW (1994) Uptake inhibitors increase extracellular serotonin concentration measured by brain microdialysis. Life Sci 55:163-167
25. Gelenberg AJ, Lydiard RB, Rudolph RL, Aguiar L, Haskins JT, Salinas E (2000) Efficacy of venlafaxine extended-release capsules in nondepressed outpatient with generalized anxiety disorder: a 6-month randomized controlled trial. JAMA 283:3082-3088
26. Hascoët M, Bourin M, Colombel MC, Fiocco AJ, Baker GB (2000a) Anxiolytic-like effects of antidepressants after acute administration in a four-plate test in mice. Pharmacol Biochem Behav 65:339-344
27. Hascoët M, Bourin M, Nic Dhonnchadha BA (2000b) The influence of buspirone, and its metabolite 1-PP, on the activity of paroxetine in the mouse light/dark paradigm and four plates test. Pharmacol Biochem Behav 67:45-53
28. Hashimoto S, Inoue T, Koyama T (1996) Serotonin reuptake inhibitors reduce conditioned fear stress-induced freezing behaviour in rats. Psychopharmacology 123:182-186
29. Hyttel J (1994) Pharmacological characterisation of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol 9:19-26
30. Kent JM (2000) SNaRIs, NaSSAs and NaRIs: new agents for the treatment of depression. Lancet 355:911-918
31. Kõks S, Beljajev S, Koovit I, Abramov U, Bourin M, Vasar E (2001) 8-OH-DPAT, but not deramciclane, antagonizes the anxiogenic-like action of paroxetine in an elevated plus-maze. Psychopharmacology 153:365-372
32. Kreiss DS, Lucki I (1995) Effects of acute and repeated administration of antidepressant drugs on extracellular levels of 5-hydroxytryptamine measured in vivo. J Pharmacol Exp Ther 274:866-876
33. Lambert O, Bourin M (2002) SNRIs: mechanism of action and clinical features. Expert Rev Neurother 2:849-858
34. Lightowler S, Kennett GA, Williamson IJ, Blackburn TP, Tulloch IF (1994) Anxiolytic-like effect of paroxetine in a rat social interaction test. Pharmacol Biochem Behav 49:281-285
35. McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH (2000) A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 57:794-801
36. Millan MJ, Gobert A, Lejeune F, Newman-Tancredi A, Rivet JM, Auclair A, Peglion JL (2001a) S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine. J Pharmacol Exp Ther 298:565-580
37. Millan MJ, Dekeyne A, Papp M, La Rochelle CD, MacSweeney C, Peglion JL, Brocco M (2001b) S33005, a novel ligand at both serotonin and norepinephrine transporters. II. Behavioral profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine. J Pharmacol Exp Ther 298:581-591
38. 2C antagonist, irindalone has the potential as add-on therapy in combination with SSRIs: Microdialysis and light dark box studies. Int J Neuropsychopharmacol 5(Suppl 1):S69
39. Muth EA, Haskins JT, Moyer JA, Husbands GE, Nielsen ST, Sigg EB (1986) Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem Pharmacol 35:4493-4497
40. Nemeroff CB (2003) Anxiolytics: past, present, and future agents. J Clin Psychiatry 64:3-6
41. 2 ligands on three mouse models of anxiety. Behav Brain Res 140:203-214
42. Nierenberg AA (2001)Do some antidepressants work faster than others? J Clin Psychiatry 62:22-25
43. Ninan PT (2000) Use of venlafaxine in other psychiatric disorders. Depress Anxiety 12:90-94
44. Njung'e K, Handley SL (1991) Effects of 5-HT uptake inhibitors, agonists and antagonists on the burying of harmless objects by mice; a putative test for anxiolytic agents. Br J Pharmacol 104:105-112
45. Owens MJ, Morgan WN, Plott SJ, Nemeroff CB (1997) Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther 283:1305-1322
46. Petersen EN, Lassen JB (1981) A water lick conflict paradigm using drug experienced rats. Psychopharmacology 75:236-239
47. Pollack MH, Zaninelli R, Goddard A (2001) Paroxetine in the treatment of generalised anxiety disorders: results of a placebo controlled, flexible-dosage trial. J Clin Psychiatry 62:350-357
48. Prut L, Belzung C (2003) The open field as a paradigm to measure the effects of drugs on anxiety-like behaviours: a review. Eur J Pharmacol 463:3-33
49. Rasmussen BB, Brosen K (2000) Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? Ther Drug Monit 22:143-154
50. Rickels K, Pollack MH, Sheehan DV, Haskins JT (2000) Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry 157:968-974
51. Rosen RC, Lane RM, Menza M (1999) Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol 19:67-85
52. Rupniak NM, Carlson EC, Harrison T, Oates B, Seward E, Owen S, De Felipe C, Hunt S, Wheeldon A (2000) Pharmacological blockade or genetic deletion of substance P (NK(1)) receptors attenuates neonatal vocalisation in guinea-pigs and mice. Neuropharmacology 39:1413-1421
53. Sanchez C (2003) Stress-induced vocalisation in adult animals. A valid model of anxiety? Eur J Pharmacol 463:133-143
54. Sanchez C, Meier E (1997) Behavioural profiles of SSRIs in animal models of depression, anxiety and aggression. Are they all alike? Psychopharmacology 129:197-205
55. Schreiber R, Melon C, De Vry J (1998) The role of 5-HT receptor subtypes in the anxiolytic effects of selective serotonin reuptake inhibitors in the rat ultrasonic vocalization test. Psychopharmacology 135:383-391
56. Stahl SM (1998) Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. J Affect Disord 51:215-235
57. Stahl SM, Entsuah R, Rudolph RL (2002) Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression. Biol Psychiatry 52:1166-1174
58. 2A receptor antagonism on the firing activity of norepinephrine neurons. J Pharmacol Exp Ther 302:983-991
59. Vaswani M, Linda FK, Ramesh S (2003) Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry 27:85-102
60. Winslow JT, Insel TR (1991) The infant rat separation paradigm: a novel test for novel anxiolytics. Trends Pharmacol Sci 12:402-404
61. Woods A, Smith C, Szewczak M, Dunn RW, Cornfeldt M, Corbett R (1993) Selective serotonin re-uptake inhibitors decrease schedule-induced polydipsia in rats: a potential model for obsessive compulsive disorder. Psychopharmacology 112:195-198
62. Zohar J, Westenberg HG (2000) Anxiety disorders: a review of tricyclic antidepressants and selective serotonin reuptake inhibitors. Acta Psychiatr Scand Suppl 403:39-49